IGI Logo

Lupin is currently trading at Rs. 1143.20, up by 4.10 points or 0.36% from its previous closing of Rs. 1139.10 on the BSE.

The scrip opened at Rs. 1144.00 and has touched a high and low of Rs. 1148.60 and Rs. 1141.50 respectively. So far 12186 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1,148.60 on 7-Sept-2023 and a 52 week low of Rs. 623.20 on 19-Sep-2022.

Last one week high and low of the scrip stood at Rs. 1148.60 and Rs. 1088.30 respectively. The current market cap of the company is Rs. 51852.96 crore.

The promoters holding in the company stood at 47.07%, while Institutions and Non-Institutions held 43.30% and 9.64% respectively.

Lupin has forged a unique collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs), a pioneer in affordable medicines, and the COPD Foundation, dedicated to enhancing the lives of COPD patients. 

This collaboration aims to bolster access to healthcare by expanding the availability of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, to COPD patients in the US. Lupin’s Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, is currently the only generic product available that is therapeutically equivalent to Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule by Boehringer Ingelheim Pharmaceuticals, Inc.

Chronic obstructive pulmonary disease (COPD) affects over 15 million adults in the US and ranks as the fourth leading cause of death in the country. This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally